Frontiers of cardiovascular polypills: From atherosclerosis and beyond

Sonali R. Gnanenthiran, Anubha Agarwal, Anushka Patel

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Fixed-dose combination (FDC) therapies (also known as polypills) remain underutilized in clinical practice despite over two decades of evidence from randomized controlled trials demonstrating increased adherence to multidrug therapy, improved cardiovascular disease (CVD) risk factor control, and lower incidence of cardiovascular events. Evidence demonstrates that FDC-based implementation strategies can substantially complement and augment current strategies for CVD risk prevention globally. The next decade is likely to extend the frontier of cardiovascular FDC therapies, particularly given expected advances in FDC manufacturing technology and accessibility. FDC-based anti-hypertensive therapies are emerging as integral components of a pragmatic blood pressure lowering strategy. Cardiovascular FDCs are rapidly approaching its coming of age, transforming from heavily hyped research tools to pragmatic clinical instruments. This review evaluates the current evidence for cardiovascular FDCs, barriers to current use, and potential next generation advances.

Original languageEnglish
Pages (from-to)182-189
Number of pages8
JournalTrends in Cardiovascular Medicine
Issue number3
StatePublished - Apr 2023


  • Atherosclerosis
  • Cardiovascular disease
  • Fixed dose combination
  • Hypertension
  • Polypill
  • Prevention


Dive into the research topics of 'Frontiers of cardiovascular polypills: From atherosclerosis and beyond'. Together they form a unique fingerprint.

Cite this